Pfizer, Inc. Press Releases

PFE 
$30.09
*  
0.20
 negative 
0.67%
Get PFE Alerts
*Delayed - data as of Apr. 16, 2014 
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Advil® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick off a Nationwide “Relief” Tour
4/14/2014 7:02:00 AM - Business Wire

TWi Announces ANDA Approval of Generic Procardia XL(R) Tablets 30 mg, 60 mg and 90 mg in the United States
4/7/2014 5:45:00 AM - PR Newswire

Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer
4/6/2014 10:30:00 AM - Business Wire

Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis
4/3/2014 8:00:00 AM - PR Newswire

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
4/1/2014 2:30:00 PM - PR Newswire

LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts
4/1/2014 8:30:00 AM - PR Newswire

American Health Strategy Project Businesses Lead the Way in Worksite Health Promotion
3/31/2014 7:30:00 AM - PR Newswire

Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR
3/28/2014 6:26:00 PM - Business Wire

Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices
3/28/2014 11:31:00 AM - PR Newswire

Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan
3/28/2014 8:00:00 AM - PR Newswire

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1
3/27/2014 8:14:00 AM - Business Wire

Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1
3/27/2014 8:00:00 AM - Business Wire

Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age
3/26/2014 8:00:00 AM - Business Wire

Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts
3/25/2014 5:10:00 PM - Business Wire

Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
3/25/2014 8:30:00 AM - Business Wire

Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
3/22/2014 11:45:00 AM - Business Wire

Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
3/21/2014 8:00:00 AM - PR Newswire

Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease
3/20/2014 8:30:00 AM - Business Wire

Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories
3/20/2014 8:00:00 AM - PR Newswire

ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence
3/19/2014 9:45:00 AM - PR Newswire

Pfizer Launches 2013 Integrated Annual Review
3/18/2014 10:00:00 AM - Business Wire

Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific, WellPoint, Aetna, and Humana
3/18/2014 8:00:00 AM - PR Newswire

U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery
3/14/2014 1:00:00 PM - Business Wire

Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent
3/12/2014 2:28:00 PM - Business Wire

Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014
3/12/2014 10:00:00 AM - Business Wire